CRYOSITE LIMITED ABN 86 090 919 476
Appendix 4DSix months ended 31 December 2016 ('current period') and 31 December 2015 ('previous corresponding period')
0BResults for announcement to the market
Details of Reporting Period
The financial information contained in this report is for the half year ended 31 December 2016. Comparative amounts (unless otherwise indicated) relate to the year ended 31 December 2015.
Results for Announcement to the Market
$A'000
2.1 Revenue from ordinary activities:
Up
4.5%
to
5,183
2.2 Profit from ordinary activities after tax attributable to members:
Up
22.8%
to
253
2.3 Net profit for the period attributable to members:
Up
22.8%
to
253
Dividends
The Board of Cryosite has on the 22nd February 2017 determined and is pleased to announce the payment of an interim unfranked dividend of 0.5 cent (half cent) per ordinary share.
Key Dates:
Ex Dividend Payment: trading commences 14th March 2017 Record Date - last date: for CTE share register 15th March 2017 Dividend payment Date 31st March 2017
Commentary on the results to the market:
An explanation of the result of the current period is set out in the Directors Report contained in the attached audit reviewed half-yearly Financial Report.
3.0 NTA backing
Current period
Previous corresponding
Period
Net tangible asset backing per ordinary security
6.1 cents
6.6 cents
8B
CRYOSITE LIMITEDABN 86 090 919 476
Half-Year Financial Report31 December2016
CR YOS ITELIMITED-HA LF- YEA R FINANC IA L REPORT
Table of Contents
Directors 'Report
Auditor'sIndependence DeclarationDirectors 'Declaration
Interim Consolidated Statement of Comprehensive Income
Interim Consolidated Statement of FinancialPosition
Interim Consolidated Statement of Changes in
Equity
Interim Consolidated Statement ofCash Flows Notes to the Half-yearFinancial Statements Independent Auditor's Review Report
PAG E NO.
1-2
3
4
5
6
7
8
9-26
27-28
CR YOS ITE LIMITE D-HA LF - Y EA R FINANCIA L REPOR T
Directors' Report
Your directors submit theirreport for thehalf-year ended 31December 2016.
Directors
The directorsof Cryosite Limited and itscontrolled entities (the"Company")in office duringthe halfyear, and untilthe date of this Reportare set out below. Directorswere inoffice for this entireperiod unlessotherwise stated.
Stephen Roberts (Non-ExecutiveChair) -appointed on 8 I12/2015 Andrew Kroger(Non-Executive Director)-appointed 21 /11/2011
Graeme Allen Moore(Executive Director) -appointed 22 /9/2008, resigned6/10/2016 Nicola Swift(Non-Executive Director) -appointed 3/11/2016
Principal Activities
Since itwas established in2000, Cryosite hasevolved intoa company that hassuccessfully integrated a numberof services including privatecord blood storage,biorepository management and specialiseddistribution of biological materials and pharmaceutical products usedinclinical trials.
The services are grouped intotwo marketsegments, IndividualisedConsumer Biologicsand Scientific Processing andLogistics.
Review of Operations
Group revenue forthehalf-year was $5,183,185 which was a 4.5% increase overthe sameperiod lastyear ($4,956,23 1) and in linewith revenueover the six monthsto June 2016($5, 180,272).Profit beforetax forthe period was$359,568,anincrease of25 %over thecorresponding periodin2015.
Cash flow remainedstrong with cash from operationsgenerating a positivecashflow of $746,916. During the periodthe Company paida finaldividend of$234,781 forthe June 2016year. Overa llcash increased by $421,61 1during theperiod.
TheCompanyrecordedan incometaxexpense of $106,527 though notall this istax ispayable due to theavailability of carried forward taxlosses.
The increaseinpre-tax profit of $72,091over the corresponding period wasdriven by a combinationof increased revenues of 4.5% and reduced expensesin respect to Marketingand Administration expense.
During the fusthalfofthis financialyear, the Company continuedto invest. TheBoardandits CEO completed the buildout ofnew senior management team,appointing anewChief Marketing Officer and Chief Operating Officer. TheCompany also further invested its regulatoryteam, responsible for ourdealing with theTherapeuticGoods Administration (TGA).
The Company continued toinvest inmarketingacross various mediaareas to build brandawareness and penetrationinthe cord bloodand tissue categoryandultimatelyour market share. The Company'sinvestment inonlinemedia continuestobesuccessful having contributedwellto revenue performanceof CordBlood and Tissuethis year. Additional investmentsinthe traditionalareas of marketingsuch
Cryosite Limited published this content on 22 February 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 23 February 2017 08:16:11 UTC.
Original documenthttp://services.cryosite.com/docs/20170222%20-%20%20App4D%20and%20signed%20half%20year%20accounts%20December%202016.pdf
Public permalinkhttp://www.publicnow.com/view/BE4F4F105EEA868AAD5ECCA27FDEBD4AB9781693
